{
  "abstract": "Introduction\n\nAtezolizumab plus bevacizumab (Atezo/Bev) has been recommended globally for patients with Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC); however, this regimen has shown modest survival benefits. Therefore, this study aimed to assess the efficacy and safety of Atezo/Bev with or without transarterial chemoembolization (TACE) as first-line treatment for BCLC C HCC.Methods\n\nThis nationwide multicenter retrospective cohort study recruited patients with BCLC stage C HCC from 14 medical centres who received TACE combined with Atezo/Bev (TACE+Atezo/Bev) or Atezo/Bev alone as first-line treatment between October 2020 and January 2025. To mitigate potential confounding imbalances between groups, propensity score matching (PSM) and stabilized inverse probability of treatment weighting (sIPTW) were applied. Overall survival (OS) was set as the primary endpoint, with progression-free survival (PFS), objective response rate (ORR), and safety assessed as the secondary endpoints.Results\n\nOf the 256 patients included in the analysis, 154 received TACE+Atezo/Bev and 102 received Atezo/Bev. After PSM, analysis of 96 patients per group showed that the TACE+Atezo/Bev group significantly extended the median OS (25.9 months vs. 15.2 months, p < 0.001) and PFS (15.8 months vs. 7.4 months, p < 0.001), compared with the Atezo/Bev group. Post-application of sIPTW, 154 patients were assigned to the TACE+Atezo/Bev group and 102 to the Atezo/Bev group, and the median OS (25.3 vs. 15.4 months, p < 0.001) and PFS (15.5 vs. 7.5 months, p < 0.001) were significantly longer in the TACE+Atezo/Bev group than in the Atezo/Bev group. A higher ORR was observed in the TACE+Atezo/Bev group compared with the Atezo/Bev group (primary cohort: 48.7% vs. 31.4%, p = 0.009; PSM cohort: 51.0% vs. 31.2%, p = 0.008; sIPTW cohort: 50.6% vs. 32.0%, p = 0.005). Moreover, Grade 3/4 adverse events (AEs) occurred in 60 patients (39.0%) in the TACE+Atezo/Bev group and 34 patients (33.3%) in the Atezo/Bev group.Conclusion\n\nCompared with Atezo/Bev alone, TACE+Atezo/Bev may significantly improve ORR, PFS, and OS as first-line treatment for BCLC stage C HCC, while maintaining an acceptable safety profile.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.",
    "Department of Interventional Therapy II, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.",
    "Department of Interventional Radiology, Harbin Medical University Cancer Hospital, Harbin, China.",
    "Department of Interventional Radiology, The First Hospital of China Medical University, Liaoning, China.",
    "Department of Interventional Treatment, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer , Tianjin, China.",
    "Department of Interventional Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.",
    "Department of Oncology and Vascular Intervention, First Hospital of Shanxi Medical University, Shanxi Provincial Clinical Research Center for Interventional Medicine, Taiyuan, China.",
    "Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, China.",
    "Department of Hepatobiliary and Pancreatic Surgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.",
    "Vascular and Interventional Department, Chongqing University Cancer Hospital, Chongqing, China.",
    "Department of Interventional Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.",
    "Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.",
    "Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.",
    "Intervention Center, West China Hospital, Sichuan University, Chengdu, China.",
    "Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 28,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Xiao-Wu Zhang"
    },
    {
      "affs": [
        0
      ],
      "name": "Li-Wei Deng"
    },
    {
      "affs": [
        0
      ],
      "name": "Yin-Gen Luo"
    },
    {
      "affs": [
        1
      ],
      "name": "Yin-Fa Xie"
    },
    {
      "affs": [
        2
      ],
      "name": "Rui-Bao Liu"
    },
    {
      "affs": [
        3
      ],
      "name": "Hai-Bo Shao"
    },
    {
      "affs": [
        4,
        5
      ],
      "name": "Tong-Guo Si"
    },
    {
      "affs": [
        6
      ],
      "name": "Dui-Ping Feng"
    },
    {
      "affs": [
        7
      ],
      "name": "Jian Wang"
    },
    {
      "affs": [
        8
      ],
      "name": "Yu Zhang"
    },
    {
      "affs": [
        9
      ],
      "name": "Qing-Dong Li"
    },
    {
      "affs": [
        10
      ],
      "name": "Hong-Tao Hu"
    },
    {
      "affs": [
        11
      ],
      "name": "Wei-Jun Fan"
    },
    {
      "affs": [
        12
      ],
      "name": "Peng Song"
    },
    {
      "affs": [
        2
      ],
      "name": "Li-Nan Yin"
    },
    {
      "affs": [
        5
      ],
      "name": "Yan Wang"
    },
    {
      "affs": [
        6
      ],
      "name": "Yi Chen"
    },
    {
      "affs": [
        7
      ],
      "name": "Tian-Shi Lv"
    },
    {
      "affs": [
        7
      ],
      "name": "Yong Xie"
    },
    {
      "affs": [
        8
      ],
      "name": "Tian-Yi Hua"
    },
    {
      "affs": [
        9
      ],
      "name": "Jing Xiao"
    },
    {
      "affs": [
        10
      ],
      "name": "Rui-Can Nie"
    },
    {
      "affs": [
        11
      ],
      "name": "Lu-Jun Shen"
    },
    {
      "affs": [
        12
      ],
      "name": "Zhi-Ming Xuan"
    },
    {
      "affs": [
        13
      ],
      "name": "Chang Liu"
    },
    {
      "affs": [
        14
      ],
      "name": "Xue-Gang Yang"
    },
    {
      "affs": [
        1
      ],
      "name": "Xu Chang"
    },
    {
      "affs": [
        0
      ],
      "name": "Xiao Li"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5895at9y6q1xh.bib",
  "cited_by": 0,
  "doi": "10.1159/lic/admag010",
  "fulltext_url": "https://europepmc.org/articles/PMC13688698",
  "id": "5895at9y6q1xh",
  "issns": [
    "2235-1795",
    "1664-5553"
  ],
  "landing_url": "https://europepmc.org/article/MED/42924094",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2721|Hepatocellular Carcinoma Treatment and Prognosis"
    ]
  ],
  "openalex": "W7220673627",
  "pdf_url": "https://europepmc.org/articles/PMC13688698?pdf=render",
  "pmcid": "PMC13688698",
  "pmid": "42924094",
  "published": "2026-09-05",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/5895at9y6q1xh.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:21:02Z",
      "native_id": "MED:42924094",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42924094"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2721|Hepatocellular Carcinoma Treatment and Prognosis",
      "subfield": "general"
    }
  ],
  "title": "Atezolizumab plus Bevacizumab with or without Transarterial Chemoembolization as First-Line Treatment for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma: A Nationwide Multicenter Retrospective Study.",
  "title_text": "Atezolizumab plus Bevacizumab with or without Transarterial Chemoembolization as First-Line Treatment for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma: A Nationwide Multicenter Retrospective Study.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:21:02Z",
  "url": "https://research.draconitic.com/paper/5895at9y6q1xh",
  "venue": "Liver cancer",
  "versions": []
}